





#### EVALUATION OF ENHANCED RECOVERY AFTER SURGERY COMBINED WITH BARIATRIC SURGERY TARGETING OPIOID PRESCRIPTIONS PROTOCOLS ON PATIENT OUTCOMES AND LENGTH OF STAY IN BARIATRIC SURGERY

Jeffrey Silverstein MD, Adam Khayat BSc, Patricia Cherasard PHD, Jun Levine MD, Anirudha Goparaju MD, Venkata Kella MD, Islam Shahidul DrPH, Collin E.M. Brathwaite MD, MS



## **Disclosure**

Jeffrey Silverstein, MD.

I do not have any relevant financial relationship(s) with any commercial interest that pertains to the content of my presentation.





## **Enhanced Recovery After Surgery Protocols (ERAS)**





#### THE OPIOID EPIDEMIC BY THE NUMBERS







#### 10.1 million



people misused prescription opioids in the past year1


#### people used methamphetamine in the past year1

50,000

people used heroin

for the first time1

0.



1.6 million

people had an opioid use


disorder in the past year1





people misused prescription pain relievers for the first time1

48,006 deaths attributed to overdosing







ending June 2020)<sup>3</sup>





### **Bariatric Surgery Targeting Opioid Prescriptions (BSTOP)**

- The initiative: reduce opioid prescriptions
  - Pre-operative education
  - Multimodal pain control during all phases of care
    - Regional analgesia
    - Minimize opioid use
  - Data collection phase follow by implementation phase
    - We implemented BSTOP immediately




METABOLIC AND BARIATRIC SURGERY ACCREDITATION AND QUALITY IMPROVEMENT PROGRAM



# **Our Protocol Highlights**

- Pre-operative
  - Patient education
  - Pain and nausea control
- Intra-operative:
  - No induction opiates!
  - Avoid gases
  - Intra-operative TAP Block
- Post-operative
  - Breakthrough opiates by provider only





### **Methods**

- Retrospective review of prospectively maintained-database
- Sleeve gastrectomy and Roux-en-Y gastric bypass patients
  - 12-month period for each group
    - Pre-intervention 8/2018 7/2019
    - Post-intervention 8/2019 10/2020\*
- Outcomes: Length of stay and Discharge opioid prescriptions
  - Additional: readmission and complication rate
- Statistical analysis: Poisson regression, SAS 9.4



## **Results: Demographics**

	Pre Intervention (N=360)	Post Intervention (N=297)	Overall (N=657)	P- value <sup>1</sup>
Demographics				
Age (Years)	<mark>44.0 (35.0 - 54.0)</mark>	<mark>47.0 (36.0 - 56.0)</mark>	<mark>45.0 (36.0 - 54.0)</mark>	<mark>0.128</mark>
BMI (kg/m2	<mark>45.7 (41.8 - 51.3)</mark>	<mark>44.7 (40.8 - 51.4)</mark>	<mark>45.4 (41.3 - 51.3)</mark>	<mark>0.281</mark>
Female gender	275 (76.4%)	235 (79.1%)	510 (77.6%)	0.403
Race				0.562
Caucasian	208(57.9%)	178(59.9%)	368(58.8%)	
African American	99(27.6%)	73(24.6%)	172(26.2%)	
Hispanic	47(13.1%)	38(12.8%)	85(13.0%)	
Other	5(1.4%)	8(2.7%)	13(2.0%)	
Hypertension	186 (51.7%)	142 (47.8%)	328 (49.9%)	0.326
Diabetes	<mark>97 (26.9%)</mark>	<mark>91 (30.6%)</mark>	<mark>188 (28.6%)</mark>	<mark>0.297</mark>
OSA	216 (60.0%)	176 (59.3%)	392 (59.7%)	0.847
GERD	256 (71.1%)	191 (64.3%)	447 (68.0%)	0.063
OA	111 (30.8%)	85 (28.6%)	196 (29.8%)	0.537

;		Pre Intervention (N=360)	Post Intervention (N=297)	Overall (N=657)	P- valu e
	Post-op ED visit	<mark>12 (3.3%)</mark>	<mark>12 (4.0%)</mark>	<mark>24 (3.7%)</mark>	<mark>0.631</mark>
	Reoperation	<mark>9 (2.5%)</mark>	<mark>8 (2.7%)</mark>	<mark>17 (2.6%)</mark>	<mark>0.876</mark>
	Bariatric Revision	78 (21.7%)	65 (21.9%)	143 (21.8%)	0.961



## **Results: Length of Stay**

- Reduced by 1 day
- No change in readmission or complication rate

Outcomes	Pre Intervention	Post Intervention	P-value
Length of Stay, median (IQR)	2.0 (1.0 - 2.0)	1.0 (1.0 - 2.0)	<0.001
Readmission	16 (4.4%)	16 (5.4%)	0.577
Complication	15 (4.2%)	19 (6.4%)	0.199




## **LOS Continued**

Factors	IRR(95% Confidence Interval)	P-value
Group (Post Intervention vs. Pre Intervention)	<mark>0.74(0.65-0.85)</mark>	<0.001
Age	1.01(1.0-1.02)	0.145
BMI	0.99(0.98-1.01)	0.255
Sex (Female vs. Male)	1.11(0.96-1.29)	0.169
Race (White vs. other)	0.90(0.76-1.05)	0.191
HTN	0.96(0.81-1.14)	0.682
DM	<mark>1.22(1.05-1.42)</mark>	<mark>0.018</mark>
OSA	0.97(0.83-1.15)	0.745
GERD	1.07(0.97-1.18)	0.19
OA	1.14(0.95-1.36)	0.194



## **Results: Discharge Opioid Prescriptions**





## **Discussion**

- Great improvement in discharge opioid prescriptions
  - Continued patient education and protocol optimization to further decrease opioid use
- Collection and interpretation of immediate post-operative opioid use
- Long term opioid use data



## Conclusion

- ERAS and BSTOP protocols reduced length stay and opioid use without increasing complications or readmissions.
- Impact on other foregut surgery procedures should be evaluated.





# **THANK YOU**

